K51
Conditions
Interventions
Group 1: Patients can participate in the study if they are receiving newly initiated therapy with Jyseleca (filgotinib) from their physician. The drug will be taken according to the valid professional
Sponsors
CED Service GmbH
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients with UC between the ages of 18 and 80 years at study inclusion. Patients who are scheduled to receive new initiation therapy with filgotinib as determined by their treating physician. Patients will be prescribed and receive therapy as part of the filgotinib subject information. Optional additional scientific examination for motion profiles: availability of a personal smartphone.
Exclusion criteria
Exclusion criteria: A planned surgical intervention with inpatient hospital admission A history of malignant disease (except for a "Non-Melanoma Skin Cancer - NMSC) Contraindications to therapy with filgotinib analogous to the SmPC
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The investigation of health status (QoL) and psychosocial well-being including exercise data in the real word setting in patients with ulcerative colitis in the long-term course in different disease phases is the primary endpoint. | — |
Secondary
| Measure | Time frame |
|---|---|
| To collect patient-reported outcomes (PROs) related to quality of life (QoL) and psychomotor profiles (fatigue, depression) in patients with active ulcerative colitis at different disease stages during the long-term course. | — |
Countries
Germany
Contacts
Public ContactSamantha Fajardo Salmon
CED Service GmbH
Outcome results
None listed